Valued at 9,400,000€, Bionure is overfunding on Capital Cell, raising more than 975,422€ from over 210 investors for 9.27% equity for its neuroprotector and myelin regenerator drug which treat Multiple Sclerosis. Bionure is a biotech-based company that is developing a new drug for the treatment of multiple sclerosis, a… Read More
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. If your are interested in reading our Privacy Policy you may read it here. Ok
